A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema
Research Grant
Administered By
Ophthalmology
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
February 1, 2016
End Date
June 19, 2018
Administered By
Ophthalmology
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
February 1, 2016
End Date
June 19, 2018